GlassScriptPhysician profile
Patricia Delgado
NPI 1417329517
$20,532.44
in general payments reported to CMS, 2019-2025
42 companies · $8,492 in 2025
The $8,492 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,408 · 2022: $4,148 · 2023: $3,592 · 2024: $1,891 · 2025: $8,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,046 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,880 · Travel and Lodging: $2,089 · Consulting Fee: $1,840 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,045.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,880.00 |
| Travel and Lodging | $2,089.34 |
| Consulting Fee | $1,840.00 |
| Education | $120.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $6,720.10 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $1,941.84 | 2021-2025 | Cosentyx |
| Abbvie INC. | $1,806.59 | 2021-2025 | |
| Janssen Biotech, INC. | $1,059.88 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $926.76 | 2021-2025 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $901.64 | 2021-2025 | Dupixent |
| Genzyme Corporation | $810.77 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $578.01 | 2022 | |
| Journey Medical Corporation | $571.45 | 2022-2023 | |
| Lilly USA, LLC | $506.56 | 2022-2025 | Ebglyss, Olumiant |
| Neurocrine Biosciences, INC. | $378.42 | 2022-2024 | Ingrezza |
| Arcutis Biotherapeutics, INC. | $316.18 | 2023 | |
| Novo Nordisk INC | $313.19 | 2021-2023 | Wegovy |
| Allergan, INC. | $296.44 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $268.86 | 2024-2025 | Opsumit, Uptravi |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.